Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 CAD | -4.76% | -3.85% | -25.93% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 78.31 | 123.8 | 93.89 | 160.9 | 139.9 | - | - |
Enterprise Value (EV) 1 | 78.31 | 123.8 | 93.89 | 160.9 | 139.9 | 139.9 | 139.9 |
P/E ratio | -6.37 x | - | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | -14.1 x | -4.66 x | -13.9 x | -6.48 x | -4.49 x | -4.36 x |
EV / FCF | - | -15 x | -5.27 x | - | -9.39 x | -6.36 x | - |
FCF Yield | - | -6.68% | -19% | - | -10.7% | -15.7% | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 35,117 | 45,362 | 58,679 | 59,606 | 69,928 | - | - |
Reference price 2 | 2.230 | 2.730 | 1.600 | 2.700 | 2.000 | 2.000 | 2.000 |
Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -8.753 | -20.13 | -11.59 | -21.58 | -31.16 | -32.09 |
EBIT | - | -12.81 | -23.03 | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - |
Net income | -11.19 | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - |
EPS | -0.3500 | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.272 | -17.81 | - | -14.9 | -22 | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -3.059 | -4.196 | -5.448 | -4.279 | -6.212 | -3.78 | -6.2 | -5.6 | -5.3 |
EBIT | -4.147 | -5.004 | -6.313 | -4.924 | -6.784 | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/28/22 | 5/12/22 | 8/10/22 | 11/14/22 | 3/30/23 | 5/16/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.27 | -17.8 | - | -14.9 | -22 | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.13 | 0.24 | 0.25 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.93% | 103M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.29% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- NGEN Stock
- Financials NervGen Pharma Corp.